GHRP-1: A Research Overview of the First GHRP

Most discussions of the growth-hormone-releasing peptides start with GHRP-2 and GHRP-6, because those two became the workhorses of the early literature. But the series begins one step earlier, with GHRP-1 — the founding member that helped establish there was a receptor for ghrelin before ghrelin itself was identified. It's a compound of mostly historical and mechanistic importance now, but understanding it clarifies the whole class. This is a research-use explainer; GHRP-1 is not in our verified-compound catalog, so nothing here is sourcing or dosing advice.

What GHRP-1 is

GHRP-1 belongs to the growth-hormone-releasing peptide (GHRP) family — the ghrelin-mimetic class of secretagogues that imitate the natural hormone ghrelin at the GHS-R1a receptor to trigger pituitary growth-hormone release. It is a small synthetic peptide built, like its siblings, with stability-conferring modifications so it survives long enough to act.

The crucial bit of history: these peptides were synthesized before anyone knew what natural ligand the receptor was for. Researchers had a family of small peptides that reliably released growth hormone, and a receptor they bound — the growth-hormone secretagogue receptor (GHS-R) — but the endogenous hormone, ghrelin, wasn't characterized until later. GHRP-1 and its series were the tools that mapped the door before the key was found.

Where it sits in the series

The early GHRP series is easiest to read as a progression rather than a set of rivals. GHRP-1 came first; GHRP-2 and GHRP-6 followed, each a distinct peptide tuned slightly differently. They share the defining trait of the generation: potent GH release bundled with non-selectivity — the tendency to also nudge cortisol and prolactin, and, in GHRP-6's case especially, to stimulate appetite via the same ghrelin pathway.

That non-selectivity is the through-line that later, cleaner secretagogues were designed against. Our GHRP-2 vs GHRP-6 comparison covers how those two siblings diverge, and the growth-hormone secretagogue mechanisms explainer maps why selectivity became the design goal that produced compounds like ipamorelin.

What the research has examined

The GHRP-1 literature is concentrated in the foundational pharmacology of the secretagogue receptor and early growth-hormone-release characterization.

• Receptor mapping. GHRP-1 was among the peptides used to characterize the GHS-R before its natural ligand was known — part of how the field established that a dedicated secretagogue receptor existed at all.
• GH-release pharmacology. Early studies measured the magnitude and kinetics of growth-hormone output, placing GHRP-1 within the potency range of its generation.
• Class behavior. The non-selectivity and desensitization themes that characterize the early GHRPs as a group apply here too, and frame how the compound is read.

As with the whole secretagogue class, the distance between "characterized in foundational and animal models" and "established as a human intervention" is wide, and GHRP-1 holds no approved human indication. The downstream biology it feeds into — pulsatile GH and IGF-1 signaling — is laid out in our GH/IGF-1 axis explainer.

How to read GHRP-1 claims critically

The same compound-level discipline applies across the secretagogue family.

1. Mind the receptor map. GHRP-1 acts on GHS-R1a — the ghrelin door — which is mechanistically distinct from the GHRH-analog route. Conflating the two pathways drives a lot of overstated claims; our GHRP vs GHRH explainer keeps them separate.
2. Don't let "first" imply "validated." GHRP-1's historical primacy says nothing about human outcome evidence, which remains thin.
3. Expect the class confounders. Non-selectivity, cortisol/prolactin effects, and desensitization are family traits — assume they're in play unless a study specifically rules them out.
4. Distrust confident human claims without trials. Specific human outcome statements unbacked by published controlled trials deserve the same skepticism as a purity figure offered without a batch-specific COA.

Where this sits in the broader peptide picture

GHRP-1 belongs to the growth-hormone-secretagogue corner of peptide research, alongside its GHRP siblings and the GHRH analogs. For the secretagogue compounds actually in our verified catalog and how they map to research aims, see the peptide reference library and the growth-hormone research goal. For the selective member the whole non-selective series was implicitly measured against, our ipamorelin research profile is the natural companion. And for how any research peptide is made and verified before it earns a place in the catalog, see how peptides are synthesized and tested.

Bottom line

GHRP-1 is the founding member of the growth-hormone-releasing peptide family — the early synthetic secretagogue that helped map the ghrelin receptor before ghrelin itself was known. It shares its generation's defining bundle: potent GH release packaged with non-selectivity and the cortisol, prolactin, and desensitization confounders that later compounds were engineered to shed. Read its "original" status as chronology rather than endorsement, expect the class confounders, keep the ghrelin and GHRH pathways distinct, and treat it as an active research compound with no validated human role. For verified compounds and where they fit, start at our research goals and buying guides.

For research use only. Not FDA-approved, not for human consumption.

Disclosure: Peptide Research Review maintains affiliate relationships with some of the suppliers we reference. Affiliate status has no influence on our research framing or our blinded, third-party lab evaluations. Read our editorial policy and methodology.